^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PTEN mutation + TP53 mutation

    i
    Other names: PTEN, Phosphatase and tensin homolog, Mutated In Multiple Advanced Cancers 1, Phosphatase And Tensin Homolog, Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase And Dual-Specificity Protein Phosphatase PTEN, MMAC1, TEP1, MMAC1 Phosphatase And Tensin Homolog Deleted On Chromosome 10, Mitochondrial Phosphatase And Tensin Protein Alpha, Phosphatase And Tensin-Like Protein, Protein Tyrosine Phosphatase, Mitochondrial PTENalpha, PTENbeta, PTEN1, CWS1, GLM2, MHAM, TP53, Tumor Protein P53, Cellular
    Entrez ID:
    7157; 5728
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    5ms
    Genomic mutations and homologous recombination deficiency (HRD) score in Japanese patients with metastatic hormone-sensitive prostate cancer (mHSPC): The impact of intraductal carcinoma of the prostate (IDC-P). (ASCO-GU 2024)
    Among Japanese mHSPC patients, IDC-P demonstrates significant associations with an elevated incidence of genetic alterations and increased HRD score, emphasizing its potential clinical significance.
    Clinical • BRCA Biomarker • Metastases
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • HRD (Homologous Recombination Deficiency) • CDK12 (Cyclin dependent kinase 12) • BRCA (Breast cancer early onset) • FOXA1 (Forkhead Box A1)
    |
    TP53 mutation • HRD • PTEN mutation • CDK12 mutation • BRCA mutation • PTEN mutation + TP53 mutation • High HRD score
    |
    Myriad myChoice® CDx Plus
    1year
    Identification and Characterization of Metabolic Subtypes of Endometrial Cancer Using a Systems-Level Approach. (PubMed, Metabolites)
    PTEN and TP53 mutations show mutually exclusive behavior between subtypes and display a difference in survival. This work identifies metabolic subtypes with distinct characteristics at the transcriptome and genome levels, highlighting the metabolic heterogeneity within EC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog)
    |
    TP53 mutation • PTEN mutation • PTEN mutation + TP53 mutation • TP53 amplification
    over1year
    Development and validation of a gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive prostate cancer (mHSPC). (ASCO-GU 2023)
    Overall, 297 pts (baseline characteristics are shown) were included: 125 treated with ADT+Docetaxel (ADT+D) (54 and 71 in training and validation cohorts, respectively), 93 with ADT, and 79 with ADT+Abiraterone or Enzalutamide (ADT+A/E). A TSGgene expression signature is predictive of taxanes benefit in mHSPC pts and may be useful to personalize the treatment in this setting. >
    Clinical • Metastases
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1)
    |
    TP53 mutation • PTEN mutation • PTEN expression • TP53 expression • PTEN mutation + TP53 mutation • TSG gene expression signature
    |
    docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate
    almost2years
    A Propensity-Matched Study to Evaluate PTEN and TP53 Mutations as Predictive Biomarkers of Survival in Newly Diagnosed IDH-Wildtype Glioblastoma after Tumor Treating Fields (ASTRO 2022)
    Screens: 16/1Purpose/Objective(s): The addition of tumor treating fields (TTF) to adjuvant temozolomide (TMZ) for newly diagnosed glioblastoma (GBM) has been shown to improve overall survival (OS) and progression-free survival (PFS)... In this propensity-matched study, PTEN and TP53 mutations were not predictive of survival for GBM patients receiving adjuvant TTF. However, adjuvant TTF was also not associated with improved survival, which may be due to unaccounted selection bias or TTF device compliance.
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    TP53 mutation • PTEN mutation • IDH wild-type • PTEN mutation + TP53 mutation
    |
    temozolomide
    over2years
    Activation of oxidative phosphorylation in TP53-inactive endometrial carcinomas with a poor prognosis. (PubMed, Int J Gynecol Cancer)
    Our analysis revealed a relationship between pathways involved in oxidative phosphorylation and poor prognosis and provides insight into potential drug targets.
    Journal
    |
    TP53 (Tumor protein P53) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • AURKA (Aurora kinase A)
    |
    TP53 mutation • PTEN mutation • PTEN mutation + TP53 mutation
    almost3years
    [VIRTUAL] Phase II study of PI3K inhibitor copanlisib in cancer patients with deleterious PTEN mutations and retained PTEN protein expression: Results from the NCI-MATCH Trial (EAY131) sub-protocol Z1H (ESMO 2021)
    of arm Z1H of the NCI-MATCH trial demonstrated that single agent copanlisib has limited activity in cancers with deleterious PTEN mutation without loss of expression.
    Clinical • P2 data
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog)
    |
    TP53 mutation • PTEN deletion • PTEN mutation • PTEN expression • PTEN mutation + TP53 mutation
    |
    Aliqopa (copanlisib)